IL316538A - Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy - Google Patents
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapyInfo
- Publication number
- IL316538A IL316538A IL316538A IL31653824A IL316538A IL 316538 A IL316538 A IL 316538A IL 316538 A IL316538 A IL 316538A IL 31653824 A IL31653824 A IL 31653824A IL 316538 A IL316538 A IL 316538A
- Authority
- IL
- Israel
- Prior art keywords
- drug conjugate
- stimulating factor
- antibody drug
- granulopoiesis stimulating
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570901P | 2017-10-11 | 2017-10-11 | |
| US201762580267P | 2017-11-01 | 2017-11-01 | |
| US201862639308P | 2018-03-06 | 2018-03-06 | |
| US201862764805P | 2018-08-16 | 2018-08-16 | |
| PCT/US2018/055354 WO2019075168A2 (en) | 2017-10-11 | 2018-10-11 | METHODS OF REDUCING SIDE EFFECTS OF DRUG-CONJUGATED DRUG THERAPY ANTI-CD30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316538A true IL316538A (en) | 2024-12-01 |
Family
ID=64477266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316538A IL316538A (en) | 2017-10-11 | 2018-10-11 | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
| IL273874A IL273874A (en) | 2017-10-11 | 2020-04-07 | A method to reduce the side effects of drug-linked anti-CD30 antibody therapy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273874A IL273874A (en) | 2017-10-11 | 2020-04-07 | A method to reduce the side effects of drug-linked anti-CD30 antibody therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11795229B2 (enExample) |
| EP (1) | EP3694559A2 (enExample) |
| JP (3) | JP2020536916A (enExample) |
| KR (2) | KR20200066676A (enExample) |
| CN (1) | CN111526893A (enExample) |
| AU (1) | AU2018347406B2 (enExample) |
| BR (1) | BR112020006892A2 (enExample) |
| CA (1) | CA3078737A1 (enExample) |
| IL (2) | IL316538A (enExample) |
| MA (1) | MA50767A (enExample) |
| MX (1) | MX2020003664A (enExample) |
| SG (1) | SG11202003352SA (enExample) |
| TW (1) | TW201922281A (enExample) |
| WO (1) | WO2019075168A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102770340B1 (ko) | 2020-06-02 | 2025-02-21 | 삼성디스플레이 주식회사 | 표시 패널 및 이를 구비하는 표시 장치 |
| KR20230047114A (ko) * | 2020-08-03 | 2023-04-06 | 제넨테크, 인크. | 공격성 비호지킨 림프종에서의 내약성 예측 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| ES2129029T5 (es) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | Inmunoestimulacion dirigida con reactivos biespecificos. |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
| ES2193143T3 (es) | 1992-03-05 | 2003-11-01 | Univ Texas | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| EP1828241A1 (en) * | 2004-12-23 | 2007-09-05 | Laboratoires Serono S.A. | G-csf polypeptides and uses thereof |
| CA2699090C (en) * | 2007-10-12 | 2016-02-02 | Seattle Genetics, Inc. | Combination therapy with antibody-drug conjugates |
| CA3051090C (en) | 2009-01-09 | 2022-04-12 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
-
2018
- 2018-10-11 WO PCT/US2018/055354 patent/WO2019075168A2/en not_active Ceased
- 2018-10-11 TW TW107135857A patent/TW201922281A/zh unknown
- 2018-10-11 CA CA3078737A patent/CA3078737A1/en active Pending
- 2018-10-11 KR KR1020207012961A patent/KR20200066676A/ko active Pending
- 2018-10-11 JP JP2020520535A patent/JP2020536916A/ja not_active Withdrawn
- 2018-10-11 CN CN201880075981.2A patent/CN111526893A/zh active Pending
- 2018-10-11 AU AU2018347406A patent/AU2018347406B2/en active Active
- 2018-10-11 BR BR112020006892-6A patent/BR112020006892A2/pt unknown
- 2018-10-11 SG SG11202003352SA patent/SG11202003352SA/en unknown
- 2018-10-11 MA MA050767A patent/MA50767A/fr unknown
- 2018-10-11 EP EP18808554.2A patent/EP3694559A2/en active Pending
- 2018-10-11 US US16/755,403 patent/US11795229B2/en active Active
- 2018-10-11 MX MX2020003664A patent/MX2020003664A/es unknown
- 2018-10-11 IL IL316538A patent/IL316538A/en unknown
- 2018-10-11 KR KR1020257025342A patent/KR20250117487A/ko active Pending
-
2020
- 2020-04-07 IL IL273874A patent/IL273874A/en unknown
-
2023
- 2023-07-18 JP JP2023116434A patent/JP7750902B2/ja active Active
-
2025
- 2025-09-25 JP JP2025158913A patent/JP2026001086A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3078737A1 (en) | 2019-04-18 |
| KR20200066676A (ko) | 2020-06-10 |
| MX2020003664A (es) | 2020-10-12 |
| JP7750902B2 (ja) | 2025-10-07 |
| MA50767A (fr) | 2020-08-19 |
| AU2018347406B2 (en) | 2025-09-04 |
| US11795229B2 (en) | 2023-10-24 |
| AU2018347406A1 (en) | 2020-04-23 |
| US20210221901A1 (en) | 2021-07-22 |
| KR20250117487A (ko) | 2025-08-04 |
| TW201922281A (zh) | 2019-06-16 |
| WO2019075168A2 (en) | 2019-04-18 |
| JP2023162163A (ja) | 2023-11-08 |
| WO2019075168A3 (en) | 2019-05-23 |
| BR112020006892A2 (pt) | 2020-10-06 |
| JP2020536916A (ja) | 2020-12-17 |
| IL273874A (en) | 2020-05-31 |
| EP3694559A2 (en) | 2020-08-19 |
| CN111526893A (zh) | 2020-08-11 |
| SG11202003352SA (en) | 2020-05-28 |
| JP2026001086A (ja) | 2026-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200306336A1 (en) | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| JP2020510671A5 (enExample) | ||
| JP2020536932A5 (enExample) | ||
| JP2015527318A5 (enExample) | ||
| JP2015531750A5 (enExample) | ||
| JP2015528818A5 (enExample) | ||
| JP2011522834A5 (enExample) | ||
| WO2005044307A3 (en) | Methods of therapy for b cell-related cancers | |
| RU2010120724A (ru) | Комбинированная терапия антителами анти-cd20 типа ii в сочетании с ингибитором протеасом | |
| JP2015523380A5 (enExample) | ||
| IL315350A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| IL316538A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| IL318938A (en) | Anti-SEZ6 antibody conjugates | |
| Ettinger | New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer | |
| JP2021501800A5 (enExample) | ||
| FI3630177T3 (fi) | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle | |
| JP2015529656A5 (enExample) | ||
| FI3880186T3 (fi) | PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi | |
| HUP0301247A2 (hu) | Antitumor terápia disztamicin származékokkal | |
| US8758758B1 (en) | Post-relapse treatment of CD30 expressing lymphomas | |
| Shivhare et al. | Role of immunomodulators in oral diseases | |
| JPWO2021062122A5 (enExample) | ||
| IL292685A (en) | Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection | |
| IL314341A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |